Skip to main content
Shenzhen Chipscreen Biosciences Co., Ltd. logo

Shenzhen Chipscreen Biosciences Co., Ltd. — Investor Relations & Filings

Ticker · 688321 ISIN · CNE100003LW0 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 967 across all filing types
Latest filing 2025-11-19 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688321

About Shenzhen Chipscreen Biosciences Co., Ltd.

https://www.chipscreen.com/en/

Shenzhen Chipscreen Biosciences Co., Ltd. specializes in the discovery and development of original small molecule innovative drugs. The company leverages its proprietary chemical genomics-based drug discovery and early evaluation platform to address unmet medical needs in oncology, metabolic diseases, and autoimmune disorders. Its portfolio includes Chidamide (Epidaza), a selective histone deacetylase (HDAC) inhibitor approved for peripheral T-cell lymphoma and advanced breast cancer, and Chiglitazar (Bilessyl), a novel PPAR pan-agonist for type 2 diabetes. Chipscreen Biosciences maintains an integrated R&D system covering drug discovery, clinical development, and commercialization, focusing on molecular mechanisms and translational medicine to provide novel therapeutic solutions.

Recent filings

Filing Released Lang Actions
深圳微芯生物科技股份有限公司对外投资管理制度（2025年11月）
Governance Information Classification · 95% confidence The document is titled '深圳微芯生物科技股份有限公司 对外投资管理制度' which translates to 'Shenzhen Microcore Biotechnology Co., Ltd. External Investment Management System'. It outlines the company's internal policies and procedures for managing external investments, including approval authorities, investment thresholds, reporting, supervision, and disclosure obligations. There are no financial statements, earnings data, or audit results presented. The document is a governance or policy manual related to investment management rather than a financial report or announcement. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Capital Update. It is a detailed governance-related document describing internal rules and procedures. Therefore, the most appropriate classification is Governance Information (CGR). The document length is 3317 characters, which is consistent with a policy document rather than a brief announcement or a full report.
2025-11-19 Chinese
自愿披露关于西奥罗尼胶囊治疗转移性胰腺导管腺癌临床试验申请获得受理的公告
Regulatory Filings Classification · 95% confidence The document is a voluntary disclosure announcement by Shenzhen Microchip Biotechnology Co., Ltd. regarding the acceptance of a clinical trial application for a new drug (Xiaoloni capsule) by the National Medical Products Administration's Drug Evaluation Center. It details the drug's basic information, clinical trial acceptance notice, and risk warnings. The document is an official announcement about a regulatory approval event related to clinical trials, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial data. It is also not a report publication announcement or certification. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-11-06 Chinese
关于回购股份事项前十名股东及前十名无限售条件股东持股情况的公告
Transaction in Own Shares Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding the shareholding status of the top ten shareholders and the top ten unrestricted shareholders prior to a share repurchase plan. It references a board meeting resolution approving a share repurchase plan and provides detailed shareholding data as of a specific date. The content focuses on shareholding information related to a share buyback, which aligns with announcements about share repurchases or capital changes. The document is relatively short (1475 characters) and does not contain financial statements or detailed financial analysis, so it is not an Annual Report, Interim Report, or Earnings Release. It is not a voting result or management change announcement. The key focus is on share repurchase and shareholder holdings, which fits best under the category of Transaction in Own Shares (POS).
2025-11-05 Chinese
关于以集中竞价交易方式回购股份的回购报告书
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding a share repurchase plan executed through centralized bidding on the Shanghai Stock Exchange. It includes specifics such as the repurchase amount, price limits, funding sources, purpose (employee stock ownership plan or equity incentives), implementation period, board approval details, and risk disclosures. The document is not a financial report or earnings release but a formal report on the company's share buyback activity. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document length and content confirm it is the actual report of the repurchase plan, not merely an announcement of a report publication or a regulatory filing. Therefore, the correct classification is POS with high confidence.
2025-11-05 Chinese
关于取得金融机构股票回购专项贷款承诺函的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen Microchip Biotechnology Co., Ltd. regarding obtaining a loan commitment letter from a financial institution specifically for a stock repurchase plan. It details the loan amount, term, and purpose related to financing the company's share buyback. The document does not contain financial statements or detailed financial results but rather updates on financing activities related to capital structure changes. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and focused on financing, not a full report or earnings release.
2025-10-31 Chinese
关于微芯生物2021年股票增值权激励计划作废部分股票增值权相关事项之法律意见书
Regulatory Filings
2025-10-31 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.